SGLT2 Inhibitor and GLP-1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross-Sectional Study
Published on: 03 November 2025
Unveiling Current Prescribing Patterns in Primary Care
Recent research highlights a critical gap in the management of newly diagnosed Type 2 diabetes mellitus (T2DM) patients, especially those with significant cardiorenal risks. Despite clear clinical guidelines advocating the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), prescription rates remain suboptimal. Only about one in five newly diagnosed patients receive these medications within three months of diagnosis. This trend persists even among patients with chronic ischemic heart disease or impaired kidney function, who stand to benefit the most from these therapies.
This study, conducted across 60 primary care clinics in West Michigan, analyzed electronic medical records of nearly 5,800 adults with new T2DM diagnoses. The results revealed that 19.9% were prescribed either an SGLT2 inhibitor or GLP-1RA. Strikingly, prescription rates for patients with chronic ischemic heart disease and those with impaired kidney function hovered around 20%, showing minimal difference from patients without these conditions. Patients with severe obesity demonstrated slightly higher prescription rates, underscoring the growing recognition of weight management in diabetes care.
Key Clinical Drivers Influencing Prescription Decisions
The analysis identified several clinical factors strongly associated with prescribing these novel antidiabetic agents. Higher body mass index (BMI), particularly values exceeding 35 kg/m², markedly increased the likelihood of receiving SGLT2 inhibitors or GLP-1RAs. Additionally, the presence of hyperlipidemia and chronic ischemic heart disease significantly raised prescription odds after adjusting for confounders.
Moreover, elevated HbA1c levels consistently predicted the initiation of these medications. This pattern suggests that clinicians may primarily associate SGLT2 inhibitors and GLP-1RAs with glycemic control rather than their established benefits in cardiovascular and renal protection. Notably, demographic factors such as age, sex, race, and kidney function showed no significant adjusted association with prescribing, although some racial groups exhibited disparities in unadjusted analyses.
Bridging the Evidence-Practice Gap in Cardiorenal Risk Management
Despite robust guideline endorsements, the translation of evidence into practice remains challenging. Clinical inertia, limited time, and knowledge gaps in primary care contribute to underutilization. Additionally, historical perceptions of GLP-1RAs as injectable therapies may deter early adoption, although the availability of oral formulations like semaglutide offers new opportunities.
Furthermore, systemic barriers such as insurance coverage and medication costs influence access. Recent improvements in Medicaid and Medicare formularies in Michigan have eased restrictions, yet high out-of-pocket expenses, particularly for GLP-1RAs, may still hinder uptake. The ongoing shortage of GLP-1RAs, partially driven by their off-label use for weight loss, further complicates access. These factors underscore the necessity for targeted provider education and systemic interventions to enhance guideline-concordant prescribing.
Strategic Recommendations for Healthcare Professionals
To optimize the management of newly diagnosed T2DM patients at cardiorenal risk, healthcare professionals should reframe their therapeutic approach. Emphasizing the cardiovascular and renal protective effects of SGLT2 inhibitors and GLP-1RAs can shift prescribing practices beyond mere glycemic control. Providers must proactively assess BMI, lipid profiles, and cardiovascular history when initiating treatment.
Moreover, addressing patient concerns about injectable therapies and clarifying the availability of oral agents can improve acceptance. Navigating insurance formularies and advocating for policy changes to reduce financial barriers remains vital. Finally, recognizing and mitigating implicit biases that contribute to racial and ethnic disparities can promote equitable care.
Conclusion: Elevating Diabetes Care Through Evidence-Based Prescribing
This comprehensive study reveals a significant underutilization of SGLT2 inhibitors and GLP-1 receptor agonists among newly diagnosed Type 2 diabetes patients with cardiorenal risks. Despite compelling evidence and clear guidelines, these agents remain underprescribed in primary care settings. Healthcare professionals must enhance their awareness and integrate these therapies early in the diabetes management continuum. By doing so, they can substantially reduce cardiovascular events and preserve renal function, ultimately improving patient outcomes.
Advancing education, streamlining medication access, and fostering equity will be key to bridging this critical care gap. For healthcare providers involved in Muslim weight management and beyond, adopting these strategies promises to transform diabetes care and mitigate the heavy burden of cardiorenal complications.
